Clinical trials: Liraglutide
Type 2 Diabetes
The Effect of Liraglutide Treatment on Postprandial Chylomicron and VLDL Kinetics, Liver Fat and de Novo Lipogenesis
This study aims to evaluate the mechanisms underlying the effect of incretin therapy on lipoprotein metabolism in subjects with type 2 diabetes and to study the effect of liraglutide on hepatic de novo lipogenesis.
- Trial name
- NCT02765399
- Testing
- Liraglutide
- Where
- Finland
- Volunteers
- 23 people
- Sponsor
- Helsinki University Central Hospital
Diabetes Mellitus
A Phase 1b Study of LAPS-Exendin in Subjects of Type 2 Diabetes Mellitus
A Phase 1b, Exploratory, Randomized, Partially Single Blinded, Placebo and Open Label Controlled, Parallel Group Study to Assess the Effects of HM11260C and an Active Comparator on Gastric Emptying and Beta-Cell Response in…
- Trial name
- NCT02059564
- Testing
- HM11260C, Victoza
- Where
- United States
- Volunteers
- 44 people
- Sponsor
- Hanmi Pharmaceutical Company Limited
Polycystic Ovary Syndrome, Obesity
Liraglutide and Metformin Combination on Weight Loss, Metabolic - Endocrine Parameters and Pregnancy Rate in Women With PCOS, Obesity and Infertility
Polycystic ovary syndrome (PCOS) is the most common endocrine disorder in women of reproductive age and one of the leading causes of infertility.
- Conditions
- Polycystic Ovary Syndrome, Obesity, Infertility, Female
- Trial name
- NCT05952882
- Testing
- Liraglutide + Metformin, Metformin
- Volunteers
- 188 people
- Sponsor
- Mỹ Đức Hospital
Type 2 Diabetes Mellitus
Short Term Effect of Liraglutide Versus Vildagliptine on Insulin Secretion and Insulin Sensitivity in Type 2 Diabetes
This is a single blind randomised controlled clinical trial in uncontrolled type 2 Diabetes mellitus patients on oral glucose lowering agents, and naive to incretinomimetic.
- Trial name
- LIRAVIS (NCT02832999)
- Testing
- sub cutaneous liraglutide, Oral Vildagliptin
- Where
- Cameroon
- Volunteers
- 14 people
- Sponsor
- Yaounde Central Hospital
Metabolism and Nutrition Disorder, Obesity
Investigation of Safety and Efficacy of Once-daily Semaglutide in Obese Subjects Without Diabetes Mellitus
This trial is conducted globally. The aim of this trial is to investigate safety and efficacy of once-daily semaglutide in obese subjects without diabetes mellitus.
- Trial name
- NCT02453711
- Testing
- semaglutide, liraglutide
- Where
- 74 sites in United States, Australia and 6 more
- Volunteers
- 957 people
- Sponsor
- Novo Nordisk A/S
Type 2 Diabetes
Effect of Liraglutide on Clock Genes
This study is undertaken to search whether glucagon-like peptide-1 (GLP-1) analogue, Liraglutide, by enhancing clock gene and AMPK-SIRT-1 mRNA expression, may reverse the metabolic abnormalities of type 2 diabetes, improving…
- Trial name
- LIR-CG (NCT02783196)
- Testing
- Liraglutide
- Where
- Israel
- Volunteers
- 14 people
- Sponsor
- Tel Aviv University
Overweight, Obesity
3mg Liraglutide for Overweight or Obesity
In this study investigators will investigate the beneficial metabolic sequelae of Liraglutide in patients with obesity or overweight; including changes in vital signs, anthropometric characteristics (weight, body mass index and…
- Conditions
- Overweight, Obesity, Infertility, Female
- Trial name
- NCT03885297
- Testing
- Saxenda, Lifestyle modification, Metabolomics
- Where
- United Kingdom
- Volunteers
- 43 people, healthy volunteers welcome
- Sponsor
- University Hospitals Coventry and Warwickshire NHS Trust
Obesity
The Effect of Liraglutide on Pancreatic Hormones and Its Size
Glucagon-like peptide-1 (GLP-1) is a gastrointestinal hormone used to treat type 2 diabetes and severe overweight (Liraglutide).The two pancreas enzymes: amylase and lipase are slightly elevated in GLP-1 treated compared with…
- Trial name
- LIRAP (NCT03520062)
- Testing
- Liraglutide (Saxenda) 6Mg/Ml Inj Pen 3Ml
- Where
- Denmark
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Nicolai Jacob Wewer Albrechtsen
Type 2 Diabetes
Durability of Combination of Insulin and GLP-1 Receptor Agonist or SGLT-2 Inhibitors Versus Basal Bolus Insulin Regimen in Type 2 Diabetes (BEYOND)
BEYOND represents an open-label, parallel, three-arm randomized controlled trial, aimed at evaluating the effects of combination therapy of fixed ratio basal insulin/GLP-1 receptor agonist (GLP-1RA) or basal insulin/SGLT-2…
- Trial name
- BEYOND (NCT04196231)
- Testing
- IDegLira, IGlarLixi, Insulin/Canaglifozin
- Where
- Italy
- Volunteers
- 258 people
- Sponsor
- University of Campania Luigi Vanvitelli
Metabolism and Nutrition Disorder, Obesity
Comparison of Liraglutide Versus Placebo in Weight Loss Maintenance in Obese Subjects: SCALE - Maintenance
This trial is conducted in North America. The aim of this clinical trial is to evaluate the potential of liraglutide to maintain long term weight loss in obese non-diabetic subjects, as well as in overweight subjects who have…
- Trial name
- NCT00781937
- Testing
- liraglutide
- Where
- 37 sites in United States, Canada
- Volunteers
- 422 people
- Sponsor
- Novo Nordisk A/S
Diabetes, Diabetes Mellitus, Type 2
Effect of Liraglutide on Blood Glucose Control in Subjects With Type 2 Diabetes
This trial is conducted in the United States of America (USA) and Canada. This trial is designed to show the effect of treatment with liraglutide when added to existing rosiglitazone and metformin combination therapy and to…
- Trial name
- LEAD-4 (NCT00333151)
- Testing
- liraglutide, rosiglitazone, metformin
- Where
- 89 sites in United States, Canada
- Volunteers
- 576 people
- Sponsor
- Novo Nordisk A/S
Non-Alcoholic Fatty Liver Disease, Type2 Diabetes
Antidiabetic Effects on Intrahepatic Fat
This was a 24-week single-center, open-label, parallel controlled group comparing gliclazide, liraglutide, and metformin effects on diabetes with nonalcoholic fatty liver disease.
- Trial name
- NCT03068065
- Testing
- Liraglutide, Metformin, Gliclazide
- Where
- China
- Volunteers
- 87 people
- Sponsor
- The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Diabetes, Diabetes Mellitus, Type 2
To Compare the Effect of Liraglutide When Given Together With Metformin With the Effect of Metformin Given Alone and With the Effect of Glimepiride and Metformin Given Together
This trial is conducted in Europe, Oceania, Africa, Asia and South America. This trial is designed to show the effect of treatment with liraglutide when adding to existing metformin therapy and to compare it with the effects of…
- Trial name
- LEAD-2 (NCT00318461)
- Testing
- liraglutide, metformin, glimepiride
- Where
- 190 sites in Argentina, Australia and 18 more
- Volunteers
- 1,091 people
- Sponsor
- Novo Nordisk A/S
Diabetes, Diabetes Mellitus, Type 2
Effect of Liraglutide or Exenatide Added to an Ongoing Treatment on Blood Glucose Control in Subjects With Type 2 Diabetes
This trial is conducted in Europe and the United States of America (USA). The aim of this trial is to compare the effect on glycaemic control of liraglutide or exenatide when added to subject's ongoing OAD (oral anti-diabetic…
- Trial name
- LEAD-6 (NCT00518882)
- Testing
- liraglutide, exenatide
- Where
- 125 sites in United States, Austria and 14 more
- Volunteers
- 467 people
- Sponsor
- Novo Nordisk A/S
T2DM (Type 2 Diabetes Mellitus)
Efficacy and Safety of the Met+SGLT-2i+GLP-1RA in Patients With Type 2 Diabetes With Poor Glycemic Control
The main objective of this study is to compare the efficacy and safety of the triple combination therapy of Met/SGLT-2i/GLP-1RA or other oral antidiabetic drugs in patients with type 2 diabetes exhibiting poor glycemic control.
- Trial name
- MESSAGE (NCT07244003)
- Testing
- Metformin, Triple Therapy of Other Oral Antidiabetic Drugs, ganagliflozin
- Where
- China
- Volunteers
- 430 people
- Sponsor
- Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Type 2 Diabetes Mellitus, Coronary Artery Disease
Effects of Agonists of Glucagon Like Peptide - 1 Receptors (GLP-1R) on Arterial Stiffness, Endothelial Glycocalyx and Coronary Flow Reserve in Patients With Coronary Artery Disease and Patients With Diabetes Mellitus
Arterial stiffness is associated with increased risk for cardiovascular disease. Moreover, the integrity of endothelial glycocalyx plays a vital role in vascular permeability, inflammation and elasticity.
- Trial name
- NCT03010683
- Testing
- Liraglutide, Metformin
- Where
- Greece
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- University of Athens
OSA
Study That Tests AD109 in Patients Taking GLP-1 Drugs
Phase 2 Safety, Efficacy and, Tolerability of Fixed Dose Combination of Aroxybutynin/Atomoxetine (AD109) in Obstructive Sleep Apnea Patients Taking Tirzepatide, Semaglutide or Liraglutide
- Trial name
- NCT06400615
- Testing
- AD109
- Where
- 4 sites in United States
- Volunteers
- 40 people
- Sponsor
- Apnimed
Diabetes Complications, Osteoporosis
The Effect of Liraglutide on Bone Turnover, Bone Mass and Bone Cell Function
The purpose of this study is to test whether liraglutide, a drug approved and widely used in the treatment of type 2 diabetes, has an effect on bone mass and bone cell function.
- Trial name
- LIRABONE (NCT02473809)
- Testing
- Liraglutide
- Where
- Denmark
- Volunteers
- 60 people
- Sponsor
- University of Aarhus
Type 2 Diabetes
A Pharmacokinetic Study Comparing the Liraglutide Injection (RD12014) and Victoza® in Healthy Chinese Subjects
To evaluate the pharmacokinetics similarity between the liraglutide injection (RD12014) produced by Sunshine Lake Pharma Co., Ltd.
- Trial name
- NCT05294536
- Testing
- Liraglutide injection,RD12014, Liraglutide injection,Victoza
- Where
- China
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Sunshine Lake Pharma Co., Ltd.
Type1 Diabetes Mellitus, Autoimmune Diabetes
Safety and Efficacy of Umbilical Cord Blood Regulatory T Cells Plus Liraglutide on Autoimmune Diabetes
The purpose of this study is to investigate the safety and therapeutic effect of ex-vivo expanded umbilical cord blood regulatory T cells adjunct with Liraglutide on autoimmune diabetes.
- Trial name
- NCT03011021
- Testing
- Liraglutide, UCB-Treg, Insulin
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Second Xiangya Hospital of Central South University